Grufity logoGrufity logo

Corbus Pharmaceuticals Holdings Inc Stock Research

CRBP

6.85USD+0.39(+6.04%)Market Closed

Market Summary

USD6.85+0.39
Market Closed
6.04%

CRBP Stock Price

CRBP RSI Chart

CRBP Valuation

Market Cap

28.6M

Price/Earnings (Trailing)

-0.67

Price/Sales (Trailing)

19.11

Price/Free Cashflow

-0.76

CRBP Price/Sales (Trailing)

CRBP Profitability

Return on Equity

-128.36%

Return on Assets

-63.86%

Free Cashflow Yield

-131.44%

CRBP Fundamentals

CRBP Revenue

CRBP Earnings

Earnings (TTM)

-42.3M

Earnings Y/Y

-6.03%

Earnings Q/Q

-23.88%

Price Action

52 Week Range

0.108.10
(Low)(High)

Last 7 days

19.1%

Last 30 days

145.5%

Last 90 days

5656.3%

Trailing 12 Months

1270%

CRBP Financial Health

Current Ratio

4.76

Debt/Equity

0.64

Debt/Cashflow

-1.77

CRBP Investor Care

Buy Backs (1Y)

0.07%

Diluted EPS (TTM)

-10.15

Peers (Alternatives to Corbus Pharmaceuticals Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
298.0B
1.4B
-3.25% 8.54%
-148.7
210.43
20.37% -37.45%
279.9B
58.1B
4.88% 1.38%
23.64
4.82
3.30% 2.55%
87.7B
12.2B
9.61% 20.63%
20.21
7.2
-24.26% -46.28%
80.8B
8.9B
6.80% 24.91%
24.32
9.05
17.91% 41.84%
23.5B
1.0B
-5.53% 16.05%
-20.81
22.69
22.88% -32.64%
11.5B
933.0M
2.93% 61.85%
-16.28
12.27
32.93% -67.99%
10.1B
1.9B
-9.77% 22.96%
13.92
5.23
14.88% 52.86%
MID-CAP
4.2B
504.0K
-19.59% 144.55%
-14.38
2.5K
-66.53% -22.12%
2.6B
363.3M
-18.37% -45.49%
-3.74
7.28
3.39% -55.81%
2.6B
204.0M
1.49% -34.21%
-4.68
12.78
13.30% 13.44%
2.3B
12.4M
-15.06% -52.42%
-3.05
181.9
- -27.34%
SMALL-CAP
1.7B
214.2M
4.81% 93.98%
20.42
7.92
52.10% 110.42%
412.2M
151.9M
1.98% -27.23%
-3.44
2.71
96.19% 40.75%
28.6M
-
145.52% 1270.00%
-0.67
19.11
-77.61% 7.22%
3.1M
94.6M
-20.08% -11.44%
-0.01
0.03
34.30% -80.65%

Financials for Corbus Pharmaceuticals Holdings

Income Statement (Last 12 Months)
(In Thousands)
* denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42021Q42021Q32021Q22021Q1
Revenue-100.0%8821,5402,6732,823
Operating Expenses-30.0%39,83556,871---
  S&GA Expenses13.9%18,69916,417---
  R&D Expenses-48.0%16,13731,062---
Interest Expenses13.6%-1,830-2,119---
Net Income7.2%-42,346-45,640---
Free Cahsflow--37,557----
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-10.2%66.0074.0082.0096.00108
  Current Assets-10.6%60.0067.0075.0088.00100
    Cash Equivalents36.6%17.0012.0026.0057.0025.00
  Net PPE-10.3%2.002.002.002.002.00
Liabilities4.5%33.0032.0033.0035.0039.00
  Current Liabilities-27.6%13.0017.0016.0015.0017.00
  Long Term Debt0%21.0021.0021.0021.00-
    LT Debt, Current32.2%10.007.005.003.00-
    LT Debt, Non Current70.3%16.009.0012.0014.0016.00
Shareholder's Equity-21.4%33.0042.0049.0061.0069.00
  Retained Earnings-2.9%-392-381-372-359-349
  Additional Paid-In Capital0.4%425423422420419
Accumulated Depreciation7.0%3.003.003.002.00-
Shares Outstanding-0.1%4.004.004.004.004.00
Float-202----
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations5.6%-37.54-39.79-31.69-36.99-48.18
  Share Based Compensation-8.4%6.006.007.008.009.00
Cashflow From Investing98.9%30.0015.0021.0027.00-73.42
Cashflow From Financing-53361600.0%-0.531*0.000.0061.00

Risks for CRBP

What is the probability of a big loss on CRBP?

100%


Probability that Corbus Pharmaceuticals Holdings stock will be more than 20% underwater in next one year

100%


Probability that Corbus Pharmaceuticals Holdings stock will be more than 30% underwater in next one year.

85.4%


Probability that Corbus Pharmaceuticals Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CRBP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Corbus Pharmaceuticals Holdings was unfortunately bought at previous high price.

Drawdowns

Returns for CRBP

Cumulative Returns on CRBP

20.5%


7-Year Cumulative Returns

1.9%


5-Year Cumulative Returns

13.0%


3-Year Cumulative Returns

What are the long-term rolling returns for CRBP?

FIve years rolling returns for Corbus Pharmaceuticals Holdings.

Annualized Returns

Which funds bought or sold CRBP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
new
-
2,365
2,365
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
sold off
-100
-
-
-%
2023-02-14
BOOTHBAY FUND MANAGEMENT, LLC
unchanged
-
-2,587
4,413
-%
2023-02-14
Knoll Capital Management, LLC
sold off
-100
-833,000
-
-%
2023-02-14
Bank of New York Mellon Corp
reduced
-6.53
-1,457
3,543
-%
2023-02-14
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
68.75
2,394
17,394
-%
2023-02-14
TWO SIGMA SECURITIES, LLC
new
-
9,339
9,339
-%
2023-02-14
Verition Fund Management LLC
sold off
-100
-22,000
-
-%
2023-02-14
TWO SIGMA ADVISERS, LP
sold off
-100
-3,000
-
-%
2023-02-14
TWO SIGMA INVESTMENTS, LP
added
366
43,004
63,004
-%

1–10 of 44

Latest Funds Activity

Are funds buying CRBP calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own CRBP
No. of Funds

Corbus Pharmaceuticals Holdings News

InvestorsObserver

Is Corbus Pharmaceuticals Holdings Inc (CRBP) a Winner in the Healthcare Sector?.

InvestorsObserver,
3 days ago

San Antonio Express-News

Schedule 13G FIlings of Corbus Pharmaceuticals Holdings

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Aug 24, 2022
etf managers group, llc
4.95%
6,194,679
SC 13G/A
Feb 14, 2022
etf managers group, llc
8.78%
10,995,143
SC 13G/A
Jun 01, 2021
etf managers group, llc
11.39%
14,240,357
SC 13G/A
May 11, 2021
etf managers group, llc
5.34%
6,673,458
SC 13G/A
Apr 12, 2021
blackrock inc.
4.5%
5,673,664
SC 13G/A
Mar 17, 2021
etf managers group, llc
4.80%
5,997,343
SC 13G/A
Feb 16, 2021
etf managers group, llc
6.96%
5,851,347
SC 13G/A
Feb 12, 2021
etf managers group, llc
9.28%
7,796,166
SC 13G/A
Jan 29, 2021
blackrock inc.
6.2%
5,220,525
SC 13G/A
Jan 11, 2021
state street corp
1.59%
1,333,546
SC 13G/A

CRBP Fair Value

Corbus Pharmaceuticals Holdings fair value in different scenarios

The table shows the Fair Value estimates for Corbus Pharmaceuticals Holdings for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

1.80

-73.72%

1.90

-72.26%

2.19

-68.03%

2.64

-61.46%

3.81

-44.38%
Current Inflation

1.79

-73.87%

1.89

-72.41%

2.15

-68.61%

2.54

-62.92%

3.56

-48.03%
Very High Inflation

1.79

-73.87%

1.87

-72.70%

2.09

-69.49%

2.42

-64.67%

3.26

-52.41%

Historical Corbus Pharmaceuticals Holdings Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Corbus Pharmaceuticals Holdings

View All Filings
Date Filed Form Type Document
Mar 10, 2023
S-8
Employee Benefits Plan
Mar 07, 2023
8-K
Current Report
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
3
Insider Trading
Mar 07, 2023
10-K
Annual Report
Mar 06, 2023
8-K
Current Report
Feb 15, 2023
8-K/A
Current Report
Feb 15, 2023
4
Insider Trading
Feb 15, 2023
4
Insider Trading
Feb 15, 2023
4
Insider Trading

Latest Insider Trading transactions for CRBP

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-10
Cohen Yuval
bought
1,003
0.264
3,800
chief executive officer
2022-08-10
Millian Craig Stuart
bought
1,272
0.2545
5,000
chief operating officer
2022-08-10
Moran Sean F.
bought
5,198
0.2599
20,000
chief financial officer
2022-05-16
Cohen Yuval
bought
2,625
0.25
10,500
chief executive officer
2022-05-16
Moran Sean F.
bought
3,600
0.3
12,000
chief financial officer
2022-03-10
Millian Craig Stuart
bought
3,700
0.37
10,000
chief operating officer
2022-03-10
Moran Sean F.
bought
5,550
0.37
15,000
chief financial officer
2022-03-09
Cohen Yuval
bought
3,182
0.37
8,600
chief executive officer
2020-12-21
Moran Sean F.
acquired
122,500
1.4
87,500
chief financial officer
2020-12-21
Moran Sean F.
sold
-153,125
1.75
-87,500
chief financial officer

1–10 of 38

Yuval Cohen
40
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]  
Revenue from awards$ 0$ 881,705
Operating expenses:  
Research and development16,136,82636,445,285
General and administrative18,698,61920,425,444
Litigation Settlement5,000,0000
Total operating expenses39,835,44556,870,729
Operating loss(39,835,445)(55,989,024)
Other income (expense), net:  
Other income (expense), net(48,773)11,899,992
Interest income (expense), net(2,132,091)(1,830,486)
Change in fair value of derivative liability96,842663,290
Foreign currency exchange gain (loss), net(427,436)(384,198)
Other income (expense), net(2,511,458)10,348,598
Net loss$ (42,346,903)$ (45,640,426)
Net loss per share, basic$ (10.15)$ (11.15)
Net loss per share, diluted$ (10.15)$ (11.15)
Weighted average number of common shares outstanding, basic4,170,6754,094,935
Weighted average number of common shares outstanding, diluted4,170,6754,094,935
Comprehensive loss:  
Net loss$ (42,346,903)$ (45,640,426)
Other comprehensive income (loss):  
Change in unrealized gain (loss) on marketable debt securities(63,647)(62,445)
Total other comprehensive income (loss)(63,647)(62,445)
Total comprehensive loss$ (42,410,550)$ (45,702,871)

CRBP Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 17,002,715$ 25,006,632
Investments42,194,29672,640,520
Restricted cash192,475192,475
Prepaid expenses and other current assets791,6162,365,010
Total current assets60,181,102100,204,637
Restricted cash477,425477,425
Property and equipment, net1,613,8152,392,696
Operating lease right of use assets3,884,2524,609,110
Other assets155,34646,385
Total assets66,311,940107,730,253
Current liabilities:  
Notes payable353,323767,938
Accounts payable2,173,9631,782,277
Accrued expenses5,999,25210,093,312
Derivative liability36,868133,710
Operating lease liabilities, current1,280,8631,136,948
Current portion of long-term debt2,795,6693,093,344
Total current liabilities12,639,93817,007,529
Long-term debt, net of debt discount15,984,42615,636,275
Other long-term liabilities22,20522,205
Operating lease liabilities, noncurrent4,675,3545,956,217
Total liabilities33,321,92338,622,226
Stockholders' equity  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2022 and December 31, 2021. See Note 1300
Common stock, $0.0001 par value; 300,000,000 shares authorized, 4,171,297 and 4,169,631 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively417416
Additional paid-in capital425,196,359418,903,820
Accumulated deficit(392,080,667)(349,733,764)
Accumulated other comprehensive loss(126,092)(62,445)
Total stockholders’ equity32,990,01769,108,027
Total liabilities and stockholders’ equity$ 66,311,940$ 107,730,253